Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma

SIMPLE SUMMARY: Belinostat is the novel histone deacetylase inhibitors (HDACis) for treatment for peripheral T-cell lymphoma (PTCL). However, the half-life of belinostat is only 1.1 h. The aim of the study was to improve the half-life and it’s in vivo circulation behavior by using liposome encapsula...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Meng-Hsuan, Weng, Jun-Yi, Chuang, Chih-Hung, Liao, Wei-Ting, Lai, Yu-Fong, Liu, Jia-Yu, Fang, Yi-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563358/
https://www.ncbi.nlm.nih.gov/pubmed/32911820
http://dx.doi.org/10.3390/cancers12092558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563358/
https://www.ncbi.nlm.nih.gov/pubmed/32911820
http://dx.doi.org/10.3390/cancers12092558

Ejemplares similares